Secondary Logo

Journal Logo

Errata

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum

doi: 10.1097/MPA.0000000000001517
  • Free

In the article “Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial,” published in the January 2020 issue of Pancreas, an error appears in the color key for Figure 2. The corrected figure appears below.

FU1
FIGURE 2:
Overall survival in NAPOLI-1 by baseline liver lesions (ITT population). Patients with baseline liver lesion data available were included in this analysis.

REFERENCE

Macarulla Mercadé T, Chen LT, Li CP, et al. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas. 2020;49:62–75.
    Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.